8:00 am
Registration & Morning Coffee
8:50 am Chair’s Opening Remarks
9:00 am Developments in Treating Prostate Cancer with RLT
Synopsis
- Integrating PSMA Radiotherapeutics into clinical practice
- Thoughts on how RLT could develop into a second/first-line therapy in coming
years
Targeting Systems to Open New Therapeutic Opportunities
9:30 am From the Death Sciences to the Life Sciences – How Radiopharmaceuticals are Revolutionizing Cancer Treatment
10:00 am Review Recent Progress in Targeting Molecules and Systems
Synopsis
- Discuss targeting systems in the conjunction with alpha-emitting therapies
- Consider Lead isotopes and Actinium-225 in depth
- Hear recent advancements with pre-targeting systems
10:30 am
Morning Networking & Refreshment Break
Designing Logical Combination Therapies
11:30 am Logical Combination Therapies for Targeted Alpha Therapies
Synopsis
- Targeted alpha therapies induce (clustered) DNA double-strand breaks leading to cell death
- Combination with inhibitors of DNA damage response may increase efficacyPotential for immune system activation
12:00 pm Pb-203/Pb-212: an Emerging Theranostic Isotopologue
Synopsis
- Theranostic pairs: what implications are there for matched and non-matched elements? Chemical, biological, developmental, logistical, commercial and regulatory aspects
- Pb-203/Pb-212 history, current state of development, and future potential.
- Next steps for radiopharmaceuticals: the curative potential of combination therapies. Targeted alpha particle therapy is showing great promise in combination with immunotherapy.
Leveraging Clinical Trial Logistics & Resources
12:30 pm Our Community Radiopharmaceutical Clinical Trials Network, Successes.
Synopsis
- What can be done to create more spaces for RLT developers to conduct trials?
- It currently takes 600 hours to train in administering RLT therapies: how can this be best addressed to spread RLT further
- Meeting the requirements for both adult patients and paediatrics
1:00 pm Scaling Up Efficiently to Meet Commercial Goals
Synopsis
- Discuss planning, and roll out of program to scale up RLT manufacturing facilities
- Consider potential bottlenecks and potential challenges of a collaborative vs. solo approach
1:30 pm
Lunch Break
Harnessing Dosimetry Studies to Improve Gain Clarity on Absorption
2:00 pm The Radiochemistry, Preclinical Efficacy & Immunogenicity Of 212Pb- Based Radiopharmaceuticals
Synopsis
- Develop radiochemistry for rapid reaction with Pb-212 and stable chelation of progeny Bi-212 daughters
- Pb-203 surrogate predicts in vivo biodistribution of Pb-212 and progeny Bi-212
- The immunogenicity of alpha-radiotherapy and synergy with immunotherapy in
melanoma
2:30 pm Panel Discussion: Striking a Balance: Achieving Anticancer Activity without Toxicity
Synopsis
- Consider how we can investigate toxicity through dosimetry and how this data can be used in regulator submissions
- Discuss how dosimetry will play a role in taking on new cancer types
- How can we overcome the lack of clarity around the application and value of
dosimetry?